Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months.

Trial Profile

Immunogenicity and Safety of Multiple Formulations of an Intramuscular Inactivated, Split Virion Swine-origin A/H1N1 Influenza Vaccine With and Without Adjuvant in Healthy European Subjects Aged 6 to 35 Months.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Jan 2014

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary) ; Adjuvants; Influenza virus vaccine
  • Indications Influenza A virus H1N1 subtype
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Sanofi
  • Most Recent Events

    • 21 Jul 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jul 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
    • 20 Apr 2011 Additional identifier (EudraCT2009-013858-32) identified in ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top